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DIFFERENTIAL DISTRIBUTION OF D4 AND D2 DOPAMINE
RECEPTORS IN RAT BRAIN: AN AUTORADIOGRAPHIC
STUDY USING [3 H]YM-09151-2
AND [3 H]RACLOPRIDE
Nancy C. Stratman, M.S.
Western Michigan University, 1995
Extrapyramidal side effects (EPS) are associated with most antipsy
chotics for the treatment of schizophrenia since these agents antagonize do
pamine D2 receptors in the nigrostriatal pathway, a brain system that regu
lates motor functions. Clozapine, an atypical antipsychotic agent in that
it does not produce EPS, was found to be more selective for the D4 than the
D2 receptor. The purpose of this study was to locate the D4 receptor in rat
brain by autoradiographic comparison studies with [3H]YM-09151-2, a D2 ,
D3 , and D4 radioligand, to [3 H]raclopride,. a D2 and D3 radioligand, in which
a subtraction would identify D4 receptor distribution. Blocking studies were
also performed by inhibiting [3 H]YM-09151-2 with raclopride and clozapine.
Receptor binding density of [3 H]YM-09151-2 was greater than
3

[

H]raclopride in mesocorticolimbic regions, a brain system involved in cog

nition and emotional stability, and clozapine blocked [3H]YM-09151-2 in
these regions. Raclopride inhibited [3 H]YM-09151-2 in nigrostriatal regions,
whereas clozapine had no effect. The investigation demonstrates that D4
receptor antagonism may result in antipsychotic efficacy without EPS.
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INTRODUCTION
Statement of the Problem
Schizophrenia is a mental disorder centrally characterized by psy
chosis defined as a break of reality usually manifested as hallucinations,
delusions, or a disruption in thought processes (Frances & Pincus, 1994).
To date, the etiology of schizophrenia is still unclear yet the dopamine hy
pothesis of schizophrenia has been the consistently used model for expla
nation of the disease. The hypothesis states that there is a dysfunction of
the dopamine neuronal system in schizophrenia, more specifically that do
pamine pathways are overactive (Carlsson, 1978; Goldstein & Deutch,
1992). Much of the evidence supporting this hypothesis is based almost en
tirely on pharmacological observations that antipsychotic drugs block dopa
mine receptors in vitro and in vivo (Anden, Butcher, Corrodi, Fuxe, & Un
gerstedt, 1970; Seeman, Lee, ChauWong, & Wong, 1976). Antipsychotic
drug treatment of schizophrenia reduces psychotic episodes in most pa
tients but virtually all agents cause unwanted motor side affects of rigidity,
tremor, akinesia, dystonia, akathisia, and tardive dyskinesia (Casey, 1989).
Some antipsychotics elicit fewer or no motor side effects and are termeq. a
typical. Presently it has not been discerned which different dopaminergic
mechanisms are involved in producing the effects of typical and atypical an-

2
ti psychotics. Recently, however, new theories on the actions of these anti
psychotic agents are emerging based on the discovery of novel dopamine re
ceptors from molecular biological techniques. The pharmacological proper
ties of the receptors and their location in the brain may provide an expla
nation for differing activity of typical and atypical antipsychotics.
Overview of Dopaminergic Pathways in Brain
In the mid 1950's dopamine's only role in the body was thought to be
exclusively as an intermediate in the biosynthesis of noradrenaline (NA)
and adrenaline (A), (Blaschko, 1939). Dopamine (DA) was first found in
significant amounts in peripheral organs of cow and sheep (Goodall, 1951;
Von Euler & Lishajko, 1957) and Carlsson, Lindquist, Magnusson, and Wal
deck (1958) showed that DA was present in the brain in equal concentra
tions to those of NA. Differences in regional distribution between the two
catecholamines DA and NA in peripheral bovine tissue and the central
nervous system led Von Euler and Lishajko (1957) and Bertler and Rosen
gren (1959) to propose that DA had a biological role independent of NA syn
thesis. Investigations by Bertler and Rosengren (1959) demonstrated that
much of the brain's DA was found in the basal ganglia. Carlsson (1959) hy
pothesized that DA in the basal ganglia regulated motor control, and DA
depletion in the striatum, a structure of the basal ganglia, may cause the
motor side effects seen in Parkinsonism. Ehringer and Hornykiewicz (1960)
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then demonstrated that DA levels were depleted in the striatum of Parkin
son patients. Development of DA research took off from this point and the
wealth of information that followed has elucidated many functions of brain
circuitry.
Dopamine is the predominant catecholamine neurotransmitter in the
mammalian brain and regulates movement, emotional stability, and neu
ron endocrine functions (Hornykiewicz, 1966a; Macloed, 1976; Caron,
Beaulieu, Raymond, Gagne, Drouin, Lefkowitz, & Labrie, 1978; Lee,
Seeman, Rajput, Farley, & Hornykiewicz, 1978; Arnt, 1987; Seeman,
1987a,b; Carlsson, 1988). Three principal dopaminergic pathways have
been described that carry out these activities (Lindvall & Bjorklund, 1981;
Bjorklund & Lindvall, 1984):
1. The nigrostriatal pathway regulates movement and partial degen
eration of this pathway contributes to the pathogenesis of Parkinson's disease.
2. The mesocorticolimbic pathway is involved in emotional stability
and a malfunctioning of this system is thought to contribute to the etiology
of schizophrenia.
3. The tuberoinfundibular pathway regulates neuroendocrine func
tioning.
The nigrostriatal and mesocorticolimbic projection systems will be dis
cussed as these are the major systems affected by antipsychotics. Since
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most of the anatomy of these DA systems are studied more extensively in
the rat, the discussion of these systems will pertain to this species. Howev
er, several observations suggest that the characteristics of these systems
are similar in all mammalian species (Divac, Bjorklund, & Passingham,
1975; Felten & Sladek, 1982) including man (Nobin & Bjorklund, 1973;
Pearson, Goldstein, Markey, & Brandeis, 1983).
Nigrostriatal Pathway
Structures involved in this DA transmission system are the substan

tia nigra (SN) and the dorsal striatum (also called caudate putamen (CPu)).
A description of their afferents and efferents and several non-dopaminergic
pathways which affect the nigrostriatal pathway will be discussed as well
as events leading to motor activation. Figure 1 shows a diagrammatic rep
resentation of these connections which are discussed below.
Afferents of the Dorsal Striatum
Dopaminergic transmission begins in neuronal cell bodies located
within the the substantia nigra (SN), predominantly the substantia nigra

pars compacta (SNc) (Dahlstrom & Fuxe, 1964; Ungerstedt, 1971; Bjork
lund & Lindvall, 1984). DA projections from the SN terminate in the dorsal
striatum (Lindvall & Bjorklund, 1978). A non-dopaminergic neocortical pro
jection system also sends afferents to the dorsal striatum (Webster, 1961;
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Major Pathways Related to Nigral Dopaminergic Innervation
of the Dorsal Striatum. Structures innervated by dopamine are
shown in black. 1 = nigrostriatal pathway, 2 = striato-pallido
pathway, 3 = striato-nigral pathway. Abbreviations: CPu =
caudate putamen, VA= ventral anterior, VL= ventral lateral,
SNc= substantia nigra pars compacta, SNr= substantia nigra
pars reticulata, 8th = subthalamic nuclei.
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Carmen, Cowan, Powell, & Webster, 1965; Donoghue & Kitai 1981).
Efferents From the Dorsal Striatum
The principal efferents of the dorsal striatum do not use dopamine as
a neurotransmitter and are channeled via two systems, the striato-pallido
and striato-nigral pathways (pathways 2 and 3 in Figure 1, respectively).
In striato-pallido efferent connections, the dorsal striatum projects to the

dorsal pallidum (Nauta & Mehler, 1966; Szabo, 1982) which in turn pro
jects to the ventral anterior (VA) and ventral lateral (VL) thalamus (Nauta
& Mehler, 1966; Nauta & Mehler, 1969). The VA-VL complex then projects
to the neocortex, more specifically the sensory motor cortex, (Penney &
Young, 1983). These cortical areas will provide connections to the pyrami

dal system, the primary pathway for initiation of voluntary movement, via
the brainstem and spinal chord (McGeer & McGeer, 1980). It is important
to note that sensory motor cortex neurotransmission has not been thought
to be modulated by dopamine. However, dopaminergic nerve terminals
have been detected in the following sensory motor cortex regions (Berger,
Verney, Alvarez, Vigny, & Helle, 1985; Descarries, Lemay, Doucet, & Ber
ger, 1987): (a) agranular frontal cortex, (b) occipital cortex, (c) parietal cor

tex, (d) posterior cingulate cortex, and (e) sensory motor overlap. The origin
of these terminals have not been determined.
In addition to this pallido-thalamic-cortical loop, the efferents of the
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dorsal pallidum project to the lateral habenula (Herkenham & Nauta, 1977;
Parent, Gravel, & Boucher, 1981). The output pathway of the habenula
provides projections to the SNc and to several areas of the mesencephalic

reticular formation (Akagi & Powell, 1968; Herkenham & Nauta, 1977; Su
therland, 1982). The mesencephalic reticular formation is an important
sensory motor integration center that has multimodal sensory inputs and
pronounced influences on motor responses (Edwards, 1980; Grillner, 1981).
The dorsal pallidum also sends projections to the mesencephalic reticular
formation (Olszewskie, 1954) and the subthalamic nucleus (Wilson, 1914),
and the subthalamic nucleus sends projections back to the dorsal pallidium
(Nauta, 1966; Carpenter, Fraser, & Shriver, 1968). The dorsal pallidum
and subthalamic nucleus also have efferents projecting to the substantia ni

gra pars reticulata (SNr) (Smith & Bolam, 1990; Smith, Bolam, & Von Kro
sigk, 1990). The SNr sends outputs to the mesencephalic reticular forma
tion (Garcia-Rill, Skinner, Gilmore, & Owings, 1983; Garcia-Rill, Skinner,
Jackson, & Smith 1983; Garcia-Rill, 1986).
The second major efferent pathway of the dorsal striatum, the
striato-nigral pathway, has efferents from the dorsal striatum projecting di
rectly to the SNr (Graybiel & Sciascia, 1975; Hattori, Fibiger, & McGeer,
1975).
Therefore, the substantia nigral neurons are modulated indirectly by
the dorsal pallidum and directly by both dorsal pallidum and dorsal stri-
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atum. The afferents of the SN are non-dopaminergic, yet dopamine release
has been seen from dendrites of the SNc neurons that run either horizontal
ly to ramify within the SNc or ventrally to ramify with the SNr (Bjorkland
& Lindvall 1975) which has been suggested to provide a variety of effects
on signal transmission within the SN (Cheramy, Leviel, & Glowinski, 1981;
Wassef, Berod, & Sotelo, 1981).
Events of Motor Activation by the Nigrostriatal System
The function of the nigrostriatal system and its associated pathways
is to provide input to the pyramidal system and the mesencephalic reticu
lar formation where both systems are involved extensively in bringing about
motor activation. The input stage of this process starts from ideas to move
which are brought to the cortex and information then proceeds to the dorsal
striatum (McGeer & McGeer, 1980). Thereafter, efferents of the dorsal stri
atum indirectly regulate the pyramidal system and the mesencephalic reti
cular formation. ·
Dopamine's major role in motor activation is to modulate striatopa
llidal and striato-nigral outputs (Gerfen, 1992). Evidence of this was shown
at the cellular level in which 90% of neurons in the dorsal striatum were
observed to project to the dorsal pallidum and SN, and the majority of these
neurons were found to express dopamine receptors (Chevalier, Vacher, De
niau, & Desban, 1985; Kita & Kitai, 1988). Behaviorally, a loss of cortex
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does not impair the locomotion process but disturbs the context in which
these movements are performed (Villablanca & Marcus, 1972; Stein, 1978;
Grillner, 1981). Furthermore, a degeneration of the SNc causes a defect in
several locomotor process, a process known to be the primary cause of Park
inson's disease (Hornykiewicz, 1966b). Thus, dopamine has a profound
modulatory influence over activities that are controlled by non-dopaminer
gic systems.
Mesocorticolimbic Pathway
The mesocorticolimbic pathway involves several terminal regions of
DA neurotransmission in contrast to the nigrostriatal system. The DA
mesocorticolimbic system was believed to originate from neuronal cells bod
ies in the ventral tegmental area (VTA) (Anden, Dahlstrom, Fuxe, Larsson,
Olson, & Ungerstedt, 1966; Ungerstedt, 1971), however projections from
both the VTA and SN were found to overlap in several terminal areas.
These pathways and the outputs of their terminal structures will be identi
fied as well as the functioning of this system in cognitive and emotional sta
bility. Figure 2 outlines these connections.
DA Efferents of the VTA and SN to Mesocorticolimbic Structures
Both VTA and SN DA efferents project to the amygdala, hippocam
pus,nucleus accumbens,olfactory tubercle,perirhinal cortex,piriform cortex,

Anterior
Cingulate
Cortex

Entorhinal
Cortex

Hipp

.

Perirhinal
Cortex

Nucleus
Accumbens

Piriform
Cortex

Temporal
Cortex

AM
ron
F
tal
Cortex

Suprarhinal
Frontal
Cortex

Medial
Dorsal
Thalamus

Olfactory
Tubercle

Ventral
Pallidum

?
Hypothalamus

Figure 2.

Substantia
Nigra

Lateral
Habenula

Mesenc
Reticular
Formation

The Mesocorticolimbic Dopamine System and Associated Pathways. Areas in black indicate struc
tures that are innervated by dopamine. Abbreviations: AM= anteromedial, CPu= caudate puta
men, Hipp. = hippocampus, mesenc. = mesencephalic, VTA = ventral tegmental area.
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and temporal cortex (Simon, Le Moal, Galey, & Cardo 1976; Carter & Fibi
ger, 1977; Fallon & Moore 1978a,b; Fallon, Koziell, & Moore, 1978; Beck
stead, Domesick, & Nauta, 1979; Bischoff, Scatton, & Korf, 1979; Simon, Le
Moal, & Calasa, 1979; Ottersan, 1981; Swanson, 1982; Bischoff, 1986).
The. VTA alone sends DA efferents to the anteromedial and supra

rhinal frontal cortex (Lindvall & Bjorklund, 1974; Beckstead, 1976; Fallon,
Koziell, & Moore, 1978; Beckstead, Domesick, & Nauta, 1979; Gerfen &
Clavier, 1979; Swanson, 1982), to the anterior medial head of the CPu (Car
ter & Fibiger, 1977; Fallon & Moore 1978b, Beckstead, Domesick, & Nauta,
1979), entorhinal cortex (Beckstead, 1978; Beckstead, 1979), and septum
(Lindvall, 1975; Lidvall & Stenevi, 1978).
The anterior cingulate cortex is innervated by the substantia nigral
DA neurons (Hokfelt, Fuxe, Johansson, & Ljungdahl, 1974; Lindvall, Bjork
lund, Moore, & Stenevi, 1974) and a contribution from VTA neurons has
been speculative (Swanson, 1982).
Dopamine found within the hypothalamus has been considered to be
associated exclusively with the tuberoinfundibular pathway (Lindvall &
Bjorklund, 1978), yet several researchers have demonstrated that DA inner
vation of the hypothalamus may be attributed to VTA and SN DA neurons
(Kizer, Palkavits, & Brownstein, 1976; Palkovits, Leranth, Zaborszky, &
Brownstein, 1977). Currently the existence of a VTA and SN DA pathway
has not been definitely established.
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Output Pathways of Mesocoritcolimbic Structures
Mesocorticolimbic structures send non-dopaminergic projections to one
or more of the following structures: (a) anterior medial CPu, (b) olfactory
tubercle, and (c) nucleus accumbens. The amygdala, anteromedial frontal
cortex, and suprarhinal frontal cortex have efferents to all three regions
(Beckstead, 1976; Kelly & Domesick, 1982; Bjorklund & Lindvall, 1984). ·
The entorhinal, perirhinal, piriform, and temporal cortices (Heimer & Wil
son, 1975; Newman & Winans, 1980; Krayniak, Meibach, & Siegel, 1981;
Kelly & Domesick, 1982) project to the accumbens and olfactory tubercle.
The hippocampal efferents proceed to the accumbens and anterior medial
CPu (Heimer & Wilson, 1975; Swanson & Cowan, 1977; Kelly & Domesick,
1982), and the anterior cingulate projects to the anterior medial CPu
(Domesick, 1969).
Two mesocorticolimbic structures that do not send projections to the
anterior medial CPu, nucleus accumbens, or olfactory tubercle are the sep
tum and hypothalamus. Both structures have efferents which project to
several mesocorticolimbic structures.
The accumbens and olfactory tubercle then send projections to the
ventral pallidum (Nauta, Smith, Faull, & Domesick, 1978; Newman & Wi
nans, 1980), VTA, and SN (Phillipson, 1979; Walaas & Fonnum, 1980), and
the anterior medial CPu projects to the ventral pallidum (Domesick, Pas
kevich, & Matthysse, 1986).
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Efferents of the ventral pallidum proceed to the mediodorsal nucleus

of the thalamus and then to the anteromedial and suprarhinal frontal cor
tex (Groenewegen & Nauta, 1982). The ventral pallidum also sends projec
tions to the mesencephalic reticular formation (Swanson, Mogenson, Gerfen,
& Robinson, 1984) and lateral habenula (Herkenham & Nauta, 1977). The
lateral habenula projects to both the mesencephalic reticular formation and
the SNc.
Circuitry of Mesocorticolimbic Structures
The conduction pathways identified do not show the complex interplay
between the mesocorticolimbic structures. For example, the anterior cingu
late cortex has projections to the mediodorsal thalamus (Hamiliton, 1976a),
the entorhinal cortex sends information to the hippocampus (Hamilton,
1976a), the septum receives inputs from the hippocampus and hypothala
mus (Hamilton, 1976b); Nauta & Feirtag, 1986), the temporal cortex sends
efferents to the entorhinal cortex and has reciprocal projections with the
amygdala (Nauta & Feirtag, 1986), and the ventral pallidum has additional
projections to the frontal cortex, amygdala, and hypothalamus (Domesick,
1988). Two structures which have extensive connections with mesocortico
limbic structures are the VTA and hypothalamus. In addition to the nucle
us accumbens and olfactory tubercle, afferents of the VTA are received from
the amygdala, frontal cortex, hypothalamus, septum, and ventral pallidum
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(Domesick, 1988). The hypothalamus receives projections from the antero
medial frontal cortex, amygdala, hippocampus, and the septum, along with
visceral exteroceptive and interoceptive information (Nauta & Feirtag,
1986). The hypothalamus sends projections to the amygdala, hippocampus,
mesencephalic reticular activating system, and VTA (Nauta & Feirtag,
1986). Consequently, there are several feedback systems associated with
mesocorticolimbic neurotransmission.
Processing of Information in Cognitive and Emotional Functioning
The genesis of cognition and emotional expression is thought to be in
timately involved with the mesocorticolimbic system. Both exteroceptive
and interoceptive information enter the hypothalamus (Nauta & Feirtag,
1986), the structure which then relays information to various mesocortico
limbic areas. In addition, vision, hearing, and somatic senses direct part
of their information to either the frontal cortex or temporal cortex (Nauta
& Feirtag, 1986) and neurotransmission also proceeds to mesocorticolimbic
structures.
The cortical and limbic components of this system are shown to be
mainly non-dopaminergic. However there is marked variations from area
to area (Swanson, 1982). The dopaminergic neurons in the mesocorticolim
bic system facilitates regulation and enables functions in the neuronal sys
tems on which they project (Simon & Le Moal, 1988). It was demonstrated
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that DA neuronal lesions in the mesocorticolimbic system causes distur
bances of behavior, and the behaviors recover to normal levels with the
introduction of dopamine (exogenously with L-DOPA (Kelley & Stinus,
1985) or endogenously by grafting embryonic DA neurons (Herman, Na
daud, Choulli, Taghzouti, Simon, & Le Moal, 1985)). Dopaminergic involve
ment in the etiology of schizophrenia has been implicated since primary
cognitive functions of cortical and limbic regions are regulated by dopamine
and antipsychotic drugs block DA receptors (Carlsson & Lindqvist, 1969;
Anden, Butcher, Corrodi, Fuxe, & Ungerstedt, 1970; Seeman, Lee, Chau
Wong, & Wong 1976).
Target of the Neurotransmitter Dopamine
Brain regions identified to have dopaminergic nerve terminals are ar
eas that use dopamine to elicit a physiological effect. Dopamine, as well as
other neurotransmitters, brings about physiological changes in a specific
manner by binding to proteins called receptors (Civelli, Bunzow, Grandy,
Zhou, & Van Tol, 1991). Dopamine receptors found in the brain are located
in the cell membranes of neurons and when bound by dopamine induce a
cascade of events within the neuron it is associated (Civelli, Bunzow,
Grandy, Zhou, & Van Tol, 1991).
Several different types of dopamine receptors exist and their locations
in the brain have lead to an understanding of the effect of dopaminergic
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drugs on disease states. Since virtually all antipsychotics have high affinity
for dopamine receptors, identifying the location of dopamine receptor sub
types in brain regions may help elucidate dopaminergic functioning in
schizophrenia. Mesocorticolimbic regions have been closely examined for
their role in schizophrenia since these brain regions are involved in cogni
tion and emotional stability and dopamine nerve terminals and dopamine
receptor mRNAs have been identified in this brain system. Additionally,
antipsychotic agents have been found to be selective for dopamine receptors
whose mRNAs are located in the nigrostriatal system and it is this specifici
ty which is thought to be responsible for extrapyramidal symptoms (EPS)
seen with drug treatment. The necessity then arises for development of an
tipsychotic agents that are specific for receptors in mesocoriticolimbic re
gions and avoid selectivity for receptors in nigrostriatal areas.
The dopaminergic structures involved in mesocorticolimbic and nigro
striatal pathways are investigated in this study in an attempt to demon
strate that a differing distribution of dopamine receptor subtypes exist in
these systems. This would provide strong implications for the discovery of
therapeutic agents that could selectively affect receptors that provide anti
psychotic efficacy without affecting brain regions which would produce EPS.
Dopamine Receptors
Five pharmacologically and structurally distinct dopamine receptors
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have been identified, the D 1 , D2, D3 , D,, and D5 , from molecular biology
techniques. These receptors fall into two categories ofdopamine receptors
termed the D 1 and D2 types (Kebabian & Calne, 1979). D 1 and D5 receptors
exhibit functional and pharmacological properties expected for the D 1 recep
tor family (Dearry, Gingrich, Falardeau, Fremeau, Bates, & Caron, 1990;
Grandy, Zhang, Bouvier, Zhou, Johnson, Allen, Buck, Bunzow, Salon, & Ci
velli, 1991), and D2 , D3 , and D4 exhibit pharmacological characteristics of
the D2 receptor family (Bunzow, Van Tol, Grandy, Albert, Salon, Christies,
Machida, Neve, & Civelli, 1988; Sokoloff, Bruno, Martes, Bouthenet, &
Schwartz, 1990; Van Tol, Bunzow, Guan, Sunhara, Seeman, Niznik, & Ci
velli, 1991).
The dopamine D2 receptor is thought to be responsible for the thera
peutic actions of antipsychotic drugs. Effective antipsychotic doses were
found to correlate linearly with their dissociation constants (�'s) at the do
pamine D2 receptor and they shared one common mechanism ofaction, that
ofD2 receptor antagonism (Seeman, Wong, & Tedesco, 1975; Seeman, Lee,
Chau-Wong, Wong, 1976; Creese, Burt, & Snyder, 1976; Seeman, 1992).
Nevertheless, these agents produce EPS and tardive dyskinesia with drug
treatment (Casey, 1989). EPS may be attributed to the D2 receptor since
high amounts ofD2 receptor mRNA were detected in the nigrostriatal sys
tem where message was found in the CPu, SNc, and SNr (Dal Toso,
Sommer, Ewert, Herb, Pritchett, Bach, Shivers, & Seeburg, 1989; Bouthe-
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net, Souil, Matres, Sokoloff, Giros, & Schwartz, 1991; Landwehrmeyer,
Mengod, & Palacios, 1993). Dopamine D:i receptors were not restricted to
the nigrostriatal system which may also explain the therapeutic efficacy of
antipsychotics as high densities of dopamine D2 receptor message was pres
ent in limbic regions consisting of the nucleus accumbens, olfactory tuber
cle, ventral tegmental area, hypothalamus, and low levels detected in the
cerebral cortex (Bouthenet, Souil, Martres, Sokoloff, Giros, & Schwartz,
1991; Landwehrmeyer, Mengod, Palacios, 1993).
Clozapine is an atypical antipsychotic in that it produces little or no
EPS or tardive dyskinesia (Casey, 1989; Fitten & Heel, 1990) and its me
chanism of action has been of interest to investigators in schizophrenia re
search. Recently clozapine was determined to have three to ten fold higher
affinity for the D4 receptor in comparison to the D2 (Van Tol, Bunzow,
Guan, Sunhara, Seeman, Niznik, & Civelli, 1991; Lahti, Evans, Stratman,
& Figur, 1993). Furthermore, the effective antipsychotic dose of clozapine
did not correlate to its � at the D2 receptor as other antipsychotics did but
did so only if its � at D4 was used (Seeman, Lee, Chau-Wong, & Wong,
1976; Seeman, 1992). The location of D4 mRNA in the rat provides addi
tional clues to clozapine's antipsychotic profile since it is detected in cortical
and limbic regions with high densities in the amygdala, frontal cortex, hipp
ocampus, and hypothalamus, and a lack of message in nigrostriatal regions
(Mansour, Meador-Woodruff, Burke, Bunzow, Akil, Van Tol, Civelli, & Wat-
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son, 1991; Van Tol, Bunzow, Guan, Sunhara, Seeman, Niznik, & Civelli,
1991).

The dopamine D3 mRNA is found in lower abundance in comparison
to dopamine D2 mRNA in rat brain and is located in limbic structures such
as the nucleus accumbens and olfactory tubercle with little detection seen
in the VTA, and sparse amounts identified in the nigrostriatal system in
cluding the CPu and substantia nigra (Bouthenet, Souil, Martres, Sokoloff,
Giros, and Schwartz, 1991; Sokoloff, Giros, Matres, Bouthenet, & Schwartz,
1991; Levesque, Diaz, Pilon, Martres, Giros, Souil, Schott, Morgat,
Schwartz, & Sokoloff, 1992; Landwehrmeyer, Mengod, & Palacios; 1993).
Clozapine's affinity for the D3 receptor is relatively low compared to the D2
and D4 receptor (Table 1) suggesting that clozapine's therapeutic effective
ness may not occur through a D3 mechanism.
The fact that clozapine has preferential affinity for D4 and D4 mRNA
is located in areas of the dopamine mesocorticolimbic pathway with a lack
ofmRNA in the nigrostriatal system suggests that these receptors may play
a role in producing antipsychotic efficacy without EPS and tardive dyskine
sia. The current working hypothesis of schizophrenia research is based on
these two major observations (Mansour, Meador-Woodruff, Burke, Bunzow,
Akil, Van Toi, Civelli, & Watson, 1991; Seeman, 1992; Strange, 1994).

Table 1
Compound Affinities(� (nM) ± S.E.) in CHO, COS, or HEK Receptor Transfected Cell Lines
Receptors
[3H]Ligand

YM-09151-2

SPIPERONE

YM-09151-2

DPAT

KETANSERIN

Compound

D2i(R)

DiR)

5-HT lA(H)

5-HTiR)

YM-09151-2

0.2±0.12·4

D4_iH)

1.0±0.092

0.5±0.06 2·6

Raclopride

2.0±0.3 1

3.5±0.3 3•5

1344.0±159.0 1

Clozapine

82.0±6.0 1

180.0±17.03•5

29.0± 2.0 1

392.0±60.01

377.0±21.02

45.0±9.0 1

6.1±0.5 2

2.9±0.1 1
137.0±9.0 2·6

1938.0±229.0 2

(+)Apo.
Haloperidol

0.9±0.3 1

Ketanserin

28.0±2.0 2·4

Pindolol

JA2,4

9.8±0.33•5
673.0±26.02
IA2

IA2,6

3.9±0.4 2

22.0±1.02
I A2

IA2
139.0±4.0 2

IA2

4.5±0.32
IA2
19.0±4.0 2
0.9±0.04 2

11.0±1.0 2

IA2

References: 1. Lahti et al., 1993, 2. Smith, M.W., 3. Sokoloff et al., 1990, 4. Ligand= [3H]U-86170, 5. Ligand
= [ 125 l]iodosulpride, 6. Ligand = [3H]spiperone.
Abbreviations: (+) Apo.=(+)apomorphine, H = human receptor, IA= inactive, R = rat receptor.

I:,:)
0

21
Purpose and Methodology of Study
This study was conducted to directly locate for the first time the D4
receptor in the rat brain by autoradiography. The distribution of the D2 re
ceptor subtypes were studied using nonselective- D2-family radioligands
since no selective ligands for these receptors exist. Dopamine D2 , D3 , and
D4 receptors were labeled with [3H]YM-09151-2 and D2 and D3 receptors
were identified with [3H]raclopride. As has been suggested previously by
Seeman, Guan, and Van Tol (1993), the difference between the two radioli
gands would represent D4 receptor distribution. Blocking studies with
3

[

H]YM-09151-2 using D2, D3 , and D4 selective compounds were also inves

tigated to further identify D4 from that ofD2 regions. The investigation at
tempts to show that dopamine D2 and D4 receptors are differentially distrib
uted, that D4 receptor density is higher than D2 in the cerebral cortex and
discrete limbic areas, and demonstrate that D2 but not D4 receptors are
found in nigrostriatal regions.

MATERIALS AND METHODS
Tissue Preparations
Male Sprague-Dawley rats (Charles River, 150-180 grams) were de
capitated and brains were quickly removed and frozen by placing them in
a metal pan surrounded by liquid nitrogen in a canister. Frozen brains
were stored in a -80°C freezer and sectioned the next day on a Leitz cryo
stat. Prior to sectioning, brains were immersed in lipshaw mounting media
and were acclimated to the cryostat chamber temperature of -20°C for ap
proximately 60 minutes. Brains were sliced 20 microns thick, thaw-mount
ed on precleaned Baxter microscope slides, and stored at -80°C until the
next day.
Incubation Medium and Autoradiographic Methods
for Receptor Binding Studies
Assay conditions were modified from Unis, Vincent, and Dillon (1990)
for [3H]YM-09151-2 and from Mansour, Meador-Woodruff, Bunzow, Civelli,
Akil, and Watson (1990) for [3H]raclopride studies. Prior to use, slides were
placed in a 37°C humidifier for 15 minutes to enhance adherence of brain
slices to slides. Slides were preincubated at room temperature (RT) for 15
minutes in 50 mM Tris-HCl buffer containing 120 mM NaCl, 5 mM MgCl2 ,
22
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1 mM EDTA, and 0.1% ascorbic acid (pH 7.4). Slides were incubated for 60
minutes at RT in the buffer described above with 1.5 nM [3H]YM-09151-2
or 3. 75 nM [3H]raclopride, which is approximately two times the� report
ed for these radioligands in whole rat brain slices (Mansour, Meador-Wood
ruff, Bunzow, Civelli, Akil, & Watson, 1990; Unis, Vincent, & Dillon, 1990).
Non-specific binding was determined by incubating alternate brain slices
with 10 µM haloperidol.
Following a 60 minute incubation period, tissues were dipped for 10
seconds in cold (4°C) 50 mM Tris-HCl buffer, pH 7.4, dipped 30 seconds in
cold Tris buffer, and rinsed twice for 10 seconds each in cold nanopure wa
ter. Slides were inserted into metal staining racks placed over ice, blown
dry on a low "cool" setting for 5 to 10 minutes, and stored in a desiccator
overnight. Slides were then placed in x-ray cassettes and exposed to triti
um sensitive Hyperfilm (Amersham). Cassettes were wrapped_in aluminum
foil and stored at 4°C for three weeks for [3H]YM-09151-2 or six weeks for
3

[

H]raclopride studies.
[

3

H]YM-09151-2 Autoradiographic Studies

Cold YM-09151-2 binds to dopamine D2-type receptors with similar
affinity (Table 1). In order to identify D4 receptor binding sites, [3H]YM09151-2 blocking studies were performed with various dopaminergic drugs.
Raclopride was used to inhibit binding at the dopamine D2 and D3 recep-
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tors, and clozapine and (+)apomorphine were used to block D4 receptors.
Equipotent concentrations ofthese compounds were determined by identify
ing their IC50's at the D2 or D4 receptor and using this value to obtain the
concentration needed to block 90% of[3H]YM-09151-2 at the receptor. Iden
tifi.cation of IC50's were obtained with the Cheng-Prusoff equation (Cheng
& Prusoff, 1973) as follows:
IC50 = � x (l+(CD]�.0))
where:
IC50 = the concentration of compound required to produce 50 percent
inhibition of radioligand at the receptor
�

= inhibition constant of compound at the receptor

[*D] = concentration of radioligand
�.0

= dissociation constant which represents the concentration ofra
dioligand that half-maximally occupies the receptor at equili
brium

Inhibition constants (�'s) of the compounds were determined from re
ceptor binding studies in CHO D2 and COS D4 receptor expressed cells and
their values are identifi.ed in Table 1. The concentration of[3H]YM-09151-2
([*DD used in autoradiographic studies was 1.5 nM, and the dissociation

constant (�.0) was obtained from Lahti, Evans, Stratman, and Figur (1993)
for [3H]YM-09151-2 at CHO D2 (0.04 nM) and at COS D4 (0.17 nM).
Raclopride's IC50 at D2 was 77 nM, therefore a concentration of 139
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nM was used to produce 90% inhibition at this receptor site, thus avoiding
D4 in which raclopride would have and IC50 of 13,203 nM. In other words,
raclopride will inhibit< 1% of [3 H]YM-09151-2 binding at the D4 receptor.
Clozapine's IC50 at D 4 was 284 nM and (+)apomorphine's was 443 nM, and
their concentrations used to block 90% of D4 receptors were 511 nM and
797 nM, respectively. At these concentrations the D4 compounds will avoid
blockade ofthe D2 receptor where clozapine and (+)apomorphine have IC50's
of 3153 nM and 15076 nM, respectively. Therefore, clozapine will inhibit
8% and (+)apomorphine 3% of [3H]YM-09151-2 binding at the D 2 receptor.
Pindolol and ketanserin were used in each incubation to prevent
[

3

H]YM-09151-2 binding to serotonin receptors as YM-09151-2 has relative

ly high affinity for serotonin receptors 5-HT 1A and 5-HT2 (Table 1). Concen
trations of serotonin specific compounds added to the incubations were de
termined by the Cheng-Prusoff equation where the I\i•n values used were
the K/s ofYM-09151-2 at the 5-HT lA (3.9 nM) and 5-HT2 (22.4 nM) recep
tors (Table 1). A 50 nM concentration of pindolol was used which is ten
times its IC50 at the 5-HT1A receptor, and 20 nM ketanserin was used and
is twenty times its IC50 at the 5-HT2 receptor.
Incubation contents were as follows: 10.7 ml of [3H]YM-09151-2, .1
ml of pindolol, .1 ml of ketanserin, and .1 ml of nanopure water for total
binding determination, .1 ml ofhaloperidol for non-specific binding, or .1 ml
of dopaminergic blocking drug.

26
3

[

H]Raclopride Autoradiographic Studies

Dopamine D2 and D3 receptors were selectively labelled by [3 H]raclo
pride, a compound which has weak affinity for D4 (Table 1). Both clozapine
and (+)apomorphine were used in blocking [3 H]raclopride studies to demon
strate their lack of D2 selectivity. Concentrations of clozapine (52 nM) and
(+)apomorphine (81 nM) used in [ H]raclopride incubations were obtained
3

in the same manner as the [3 H]YM-09151-2 studies with the Cheng-Prusoff
equation by determining their IC50 's at the CHO D, receptor and using a
concentration that would block 90% of dopamine D4 receptors labelled by
3

[

H]raclopride. Their K;'s at the D, receptor are identified in Table 1 and

the concentration of [3H]raclopride ([!)]) used was 3 .75 nM. The �.0 of
[3 H]raclopride at the D, receptor has not been determined therefore its�
at D, was used (1344 nM, Table 1). The% blockade of these compounds at
D2 were determined by using the� of cold raclopride at the D2 receptor in
Table 1 (2.0 nM) as the �.0 of [3H]raclopride and inserting this value in
the Cheng-Prusoff equation along with the compounds�'s at the CHO D2
receptor identified in Table 1. At the concentrations used, clozapine will
block 11% and (+ )apomorphine 4% of D2 receptors.
Incubation conditions were 10.9 ml of [3 H]raclopride, .1 ml of nano
pure water for total binding, .1 ml of haloperidol for non-specific binding,
or .1 ml of dopaminergic drug.
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Film Development and Analysis
Hyperfilm was developed in Kodak D-19 (5 minutes at RT), agitated
in distilled water (30 seconds RT), fixed in Kodak Rapidfix (4 minutes RT),
washed under running water (20 minutes RT), and air dried.
Autoradiographs were analyzed with the computer assisted image an
alyzer RAS-Rl00 (Research Analysis System, Loats Inc.) using tritium
standards (Amersham Microscales) calibrated for brain grey matter absorp
tive features which were exposed to the film along with the labelled sec
tions. Optical densities were converted to tissue equivalents giving receptor
densities expressed in fmol/mg of tissue. Tissue equivalent values ranged
from 1.3 to 33.0 nCi/mg tissue on the high scales used for both [3H]YM09151-2 and [3H]raclopride studies, and 0.07 to 6.0 nCi/mg tissue on the low
scales used for only [3H]raclopride studies.
Autoradiographic Data Acquisition
Three rat brain planes were investigated for both [3H]YM-09151-2 and
3

[

H]raclopride studies. Coronal sections were taken at bregma levels 3.7,

1.2, -2.8, and -4.8 mm, sagittal sections at lateral levels 0.9, 1.4, 1.9, and
2.4 mm, and horizontal sections at interaural 5.4, 4.4, 3.4, and 1.9 mm. Six
rat brain slices were used for each coronal region and treatment group,
three slices from each of two rat brains. Four rat brain slices were used for
each sagittal region and treatment group, two slices from each of two rat

28
brains. Horizontal studies used four rat brain slices for each horizontal re
gion and treatment group, one brain slice from each of four rat brains.
Coronal [3H]-YM-09151-2 binding studies were performed three times, and
both sagittal and horizontal studies were done in duplicate. Binding stud
ies of [3H]raclopride experiments were done once.
Brain structures quantified were those innervated or may be innerva
ted by dopaminergic nerve cells originating in the SNc and VTA as identi
fied in Figure 1 and 2. Bilateral measurements were made for structures
in coronal and horizontal brain slices, whereas only one measurement/slice
could be obtained for sagittal regions. Rat brain structures were identified
and named according to the rat brain atlas of Paxinos and Watson (1986).
Values of specific binding for each treatment group were obtained by sub
tracting non-specific binding from total binding. Specific bound measure
ments from similar brain areas for each of the three planes were pooled to
gether and a mean value.was obtained. Data was analyzed using one-way
analysis of variance with subsequent Student t-tests.
Chemicals
[

3

H]YM-09151-2 (specific activity 83.9 or 81.4 Ci/mmol) and [3H]raclo

pride (specific activity 79.5 Ci/mmol) were purchased from DuPont New
England Nuclear, (+)apomorphine from Research Biochemicals Inc., raclo
pride from Astra Arcus, and pindolol, ketanserin, and haloperidol were ob-
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tained from the Upjohn Co.

RESULTS
Comparison of [3H]YM-09151-2 to [3H]Raclopride Binding
The density of receptors in the SNc, SNr, and vrA determined using
[3H]YM-09151-2 was not significantly different from the amount of recep
tors labelled by [3H]raclopride (Figure 3). These brain regions have been
identified as D2 rich areas with sparse amounts of D3 which suggests that
D 2 and D 3 receptor densities determined using [3H]YM-09151-2 will be e
quivalent to D 2 and D3 densities detected by [3H]raclopride. Therefore,
brain areas that have [3H]YM-09151-2 receptor densities above [3H]raclo
pride would represent binding at dopamine D4 receptors. Receptor density
of [3H]YM-09151-2 was greater than [3H]raclopride in the cerebral cortex,
basolateral amygdala, hippocampus, septum, nucleus accumbens, and ol
factory tubercle (Figure 3), thus D 4 receptors are found in these brain re
gions.
It is important to note that [3H]YM-09151-2 binds to less receptors
than [3H]raclopride in the CPu (Figure 3). Theoretically radioligands were
expected to show equivalent binding densities in this D 2 rich brain region.
Since Bmax (i.e. maximum receptor density) values determined from radioli
gand saturation analysis is not being compared in this study, it is possible
that D2 receptor saturation is not met in [3H]YM-09151-2 investigations and
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Figure 3.

Binding Densities of [3H]YM-09151-2 and [3H]Raclopride in Rat
Brain Structures. Specific binding values obtained from Tables
2-5. Abbreviations: B.L. = basolateral, CPu = caudate puta
men, D.L. = dorsal lateral, N. = nucleus, SNc and SNr =
substantia nigra pars compacta and reticulata, respectively,
V.M. = ventral medial, VTA = ventral tegmental area. * =
p<.05 vs [3H]YM-09151-2 using analysis of variance and
subsequent t-tests.
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may explain the 14.5% decrease of [3H]YM-09151-2 binding in the CPu.
However, this may be characteristic only to the CPu as a reduction of bind
ing was not seen in any other structure. There is a possibility that the de
crease may be attributed to ketanserin binding to 5-HT2 receptors located
in this structure (Pazos, Cortes, & Palacios, 1985) which may allosterically
affect [3H]YM-09151-2 binding to D 2 receptors. An explanation for the ra
dioligand binding differences in the CPu can not be determined at this time.
However, [3H]raclopride binding will be either higher or equivalent to
3

[

H]YM-09151-2 in brain regions that express dopamine D 2 or D3 receptors,

and the conclusion can still be made that brain regions that demonstrate
a higher density of[3H]YM-09151-2 binding in comparison to [3H]raclopride
would represent binding to D4 receptors.
H]YM-09152-2 and [3H]Raclopride Blocking Studies

3

[

Values of [3H]YM-09151-2 specific binding to individual brain struc
tures in the absence and presence of dopaminergic drug were combined and
divided into the following four brain regions presented i� Figure 4: (1) sen
sory motor neocortex, (2) limbic neocortex, (3) limbic brain, and (4) nigro
striatal system. Raclopride significantly inhibited radioligand binding in
limbic and nigrostriatal regions with no effect in the sensory motor neo
cortex. Clozapine affected binding in sensory motor neocortex and limbic
regions, and had no effect in the nigrostriatal system. All four brain sys-
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terns were affected by (+)apomorphine.
The effects of the raclopride, clozapine, and (+)apomorphine on
[

H]YM-09151-2 and [3H]raclopride binding to individual brain structures

3

in the four composite brain regions are identified in Tables 2-5. The
inhibition of [3H]YM-09151-2 binding by raclopride in all quantified rat
brain structures correlated well with [3H]raclopride binding in the same
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Figure 4.

Effect of Dopaminergic Drugs on [3H]YM-09151-2 Binding in
Rat Brain Regions. Sensory motor neocortex structures iden
tified in Table 2, limbic neocortex structures in Table 3, limbic
brain areas in Table 4 (excludes accumbens and olfactory tuber
cle), and nigrostriatal structures included only the CPu values
in Table 5. * = p<.05 vs control using analysis of variance and
subsequent t-tests.

Table 2
Effect of Dopaminergic Drugs on [3H]YM-09151-2 and [3H]Raclopride Binding in
Rat Sensory Motor Neocortex
[3H]YM-09151-2 SB (fmol/mg tissue)

[

3

H]Rac. SB (fmol/mg tissue)
(+)Apo.

Control

Raclopride

Clozapine

(+)Apo.

Control

Clozapine

Fr. (1.2)

39.1±1.6

37.3±1.6

28.0±1.4*

24.6±3.1*

6.2±0.4

7.0±0.4

8.1±0.6*

Fr. I (Sagittals)

32.0±2.1

29.7±2.1

15.9±2.4*

17.1±3.0*

3.3±0.5

3.0±0.5

1.8±0.3*

Occipital CTX

29.0±1.0

26.2±1.0

17.9±1.0*

19.3±1.3*

3.3±0.2

4.2±0.3*

3.3±0.4

Parietal CTX

30.4±1.1

24.0±1.1*

18.5±1.2*

18.3±1.3*

3.8±0.3

4.8±0.4*

3.8±0.4

RSA

27.0±1.3

19.9±1.5*

19.1±1.8*

19.9±1.7*

4.1±0.4

4.3±0.5

3.9±0.4

RSG

23.8±1.3

19.2±1.3*

16.3±1.7*

18.7±1.6*

4.6±0.4

5.1±0.6

3.9±0.5

Fr. CTX (-2.8)

32.2±1.9

27.4±1.9

24.9±2.0*

17.8±1.9*

3.8±0.7

3.4±0.9

4.7±0.5

Hindlimb CTX

30.5±1.8

28.1±1.8

20.3±1.9*

16.9±1.9*

2.9±0.4

2.9±0.5

2.8±0.5

SM Neocortex
Agranular Fr. CTX

P. Cingulate CTX

SM Overlap

* p<.05 vs control using one way analysis of variance with subsequent t-tests.
Abbreviations: (+)Apo. = (+)apomorphine, CTX = cortex, Fr. = frontal, P.= posterior, Rae. = raclopride, RSA
= retrosplenial agranular cortex, RSG = retrosplenal granular cortex, SM= sensory motor. Individual brain
areas are defined in parenthesis; 1.2 and -2.8 are bregma levels (mm) of coronal sections.

Table 3
Effect of Dopaminergic Drugs on [3H]YM-09151-2 and [3H]Raclopride Binding in
Rat Limbic Neocortex
[

3

H]YM-09151-2 SB (fmol/mg tissue)

[

3

H]Rac. SB (fmol/mg tissue)

Control

Raclopride

Clozapine

(+)Apo.

Control

Clozpaine

(+)Apo.

Cingulate

44.0±2.1

29.7±2.3*

25.5±2.0*

20.9±2.4*

3.8±0.2

3.2±0.3

2.3±0.5*

Fr.2 (3.2)

42.5±2.7

29.3±2.6*

27.7±2.3*

29.8±4.4*

2.9±0.4

2.9±0.6

2.0±0.6

Fr.2 (Sagittals)

32.0±2.4

27.4±2.0

13.4±2.3*

17.1±2.7*

3.4±0.5

3.0±0.5

1.9±0.4*

AI

36.0±1.9

25.9±2.1*

22.3±2.1*

18.3±2.3*

3.5±0.4

4.1±0.5

1.9±0.4*

Fr.l (3.2)

41.8±2.3

27.1±2.6*

27.5±2.1*

26.1±2.5*

2.8±0.5

3.3±0.6

2.3±0.8

Fr.3 (3.2)

40.2±2.3

29.0±2.3*

24.4±2.3*

25.0±2.6*

3.7±0.5

3.7±0.8

2.1±0.7

28.4±1.4

23.5±1.4*

16.0±1.6*

14.8±1.9*

3.5±0.3

3.8±0.3

3.2±0.3

Limbic Neocortex
AM Fr. CTX

SR Fr. CTX

Temporal CTX

* p<.05 vs control using analysis of variance with subsequent t-tests
Abbreviations: AI = agranular insular cortex, AM = anteromedial, (+)Apo. = (+)apomorphine, CTX = cortex,
Fr. = frontal, Rae. = raclopride, SR = suprarhinal. Individual brain areas are defined in parentheisis; 3.2 is
bregma level (mm) of coronal sections.
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Table 4
Effect of Dopaminergic Drugs on [3H]YM-09151-2 and [3H]Raclopride Binding in
�t Limbic Brain Regions
[

3

H]YM-09151-2 SB (fmol/mg tissue)

[

3

H]Rac. SB (fmoVmg tissue)

Control

Raclopride

Clozapine

(+)Apo.

Control

Clozapine

(+)Apo.

147.5±2.4

88.5±2.8*

134.8±3.6*

121.5±2.9*

118.0±5.0

110.4±4.0

52.5±2.5*

APir, PMCo

40.5±2.5

39.9±2.4

33.3±3.8

25.4±2.2*

1.9±0.6

5.3±1.1

5.4±0.5

Basolateral

34.2±3.5

26.9±3.1

23.8±3.3*

19.5±2.7*

7.2±2.0

6.7±1.3

3.9±0.7

Cort.IBM

31.9±3.9

33.0±4.5

23.1±4.0

12.9±3.2*

3.0±0.9

3.0±0.9

4.8±1.0

Anterior

28.9±4.5

20.9±3.8

17.8±4.9

13.9±4.3*

16.0±0.6

9.3±1.6*

12.3±1.4

Medial

49.4±6.6

31.7±5.2

35.5±4.6

11.8±4.8*

11.3±1.5

9.7±1.1

3.3±0.6*

Lateral

34.4±7.8

24.7±7.0

32.5±6.6

17.0±5.9

7.1±2.0

5.3±0.8

0.9±0.8*

37.7±1.8

41.0±1.6

27.5±1.5*

24.1±2.6*

6.9±0.4

7.9±0.4

8.3±1.0

DG

42.0±2.0

43.2±2.0

11.6±2.3*

-10.5±2.3*

4.4±0.4

4.6±0.4

4.9±0.6

CAl

38.6±1.5

38.2±1.6

19.1±1.6*

5.4±1.7*

3.9±0.3

4.9±0.3

4.7±0.4

CA2

33.0±1.5

32.3±1.4

16.3±1.7*

6.4±1.8*

4.0±0.4

4.5±0.4

4.9±0.5

CA3

36.2±1.6

38.4±1.7

17.4±1.7*

5.1±2.1*

4.1±0.4

4.1±0.5

4.2±0.5

Limbic Region
Accumbens
Amygdala

A. Cingulate
Hippocampus

Table 4-Continued
[

3

H]YM-09151-2 SB (fmol/mg tissue)

Limbic Region

Control

Raclopride

Clozapine

(+)Apo.

Entorhinal CTX

35.8±2.2

30.9±2.2

21.1±2.0*

11.0±2.4*

Anterior

59.7±6.2

29.1±5.3*

49.7±4.7

Posterior

81.5±11.4

39.3±10.0*

Dorsal

48.8±3.0

Ventral

[3H]Rac. SB (fmol/mg tissue)
Control

Clozapine

(+)Apo.

4.6±0.6

5.2±0.5

3.8±0.4

44.5±6.2

22.4±3.3

20.5±4.0

4.8±0.7*

57.5±8.5

57.1±11.6

22.3±1.7

12.3±1.8*

5.3±0.7*

26.6±3.1*

35.3±4.2*

34.3±3.4*

20.6±1.1

19.9±1.7

42.5±4.0

25.3±4.7*

33.2±3.9

28.5±3.7*

8.0±1.0

9.7±2.0

6.1±1.5

Medial

49.2±5.1

50.4±6.6

48.4±4.7

45.4±7.7

9.0±0.9

8.8±0.6

9.8±0.9

Lateral

40.6±5.0

34.1±6.9

28.5±9.5

28.3±6.5

19.5±1.8

17.0±1.2

7.1±1.2*

Olfactory Tub.

155.9±2.8

95.5±2.6*

142.6±2.2*

126.1±2.6*

117.5±5.8

105.8±4.2

58.5±3.2*

Perirhinal CTX

29.4±2.1

23.5±1.9*

20.9±1.7*

13.5±1.7*

3.1±0.5

3.7±0.4

3.4±0.4

Piriform CTX

34.8±2.0

27.0±1.8*

21.4±1.7*

17.5±1.9*

3.3±0.8

5.0±0.9*

5.1±0.8*

Septum

53.4±2.7

42.1±2.6*

29.9±3.1*

10.4±2.9*

11.8±0.9

13.6±1.0

8.3±0.9*

VTA

58.4±4.7

38.1±3.7*

55.9±4.1

59.1±3.7

59.4±2.6

64.9±4.0

47.4±5.3*

Hypothalamus

15.9±1.8*

* p<.05 vs control using one way analysis of variance with subsequent t-tests
Abbreviations: A. = anterior, APir = amygdalopiriform transition, (+)Apo. = (+)apomorphine, BM= basomedial
amygdala, cort. = cortical amygdala, CTX= cortex, DG= dentate gyrus, CAl-3= fields of Ammon's horn, PMCo
= posteromedial cortical amygdala, Rae. = raclopride, Tub. = tubercle, VTA = ventral tegmental area.

Table 5
Effect of Dopaminergic Drugs on [3H]YM-09151-2 and [3H]Raclopride Binding in
Rat Nigrostriatal Brain Regions
(

3

H]YM-09151-2 SB (fmol/mg tissue)

(

3

H]Rac. SB (fmol/mgtissue)

Control

Raclopride

Clozapine

(+)Apo.

Control

Clozapine

(+)Apo.

D. Lateral

195.7±1.6

132.5±2.1*

190.4±1.6*

158.8±2.1*

235.9±5.7

221.3±7.0

115.9±4.7•

V. Medial

184.7±1.8

120.3±2.1*

178.8±1.7*

146.0±2.1*

209.1±4.4

195.1±5.1*

98.1±3.2*

SNc

87.4±4.5

53.4±2.8*

82.2±4.1

75.1±3.5*

78.3±4.2

78.6±3.4

43.5±3.5*

SNr

52.4±3.1

37.3±2.0*

48.7±2.8

44.6±2.7*

44.1±2.7

44.2±2.8

32.3±2.2*

NS Region
DS (CPu)

* p<.05 vs control using one-way analysis of variance with subsequent t-tests
Abbreviations: (+)Apo.= (+)apomorphine, D. dorsal, DS= dorsal striatum, CPu= caudate putamen, NS=
nigrostriatal, SNc= substantia nigra pars compacta, SNr= substantia nigra pars reticulata, V.= ventral.

�
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structures (r = 0.87; p<.05). Thus, raclopride inhibition of [3H]YM-09151-2
would indicate blockade at D2 or D3 receptors. Since D3 receptor distribu
tion is sparse in comparison to D2 , raclopride effects on [3H]YM-09151-2
binding can be attributed to binding at the D2 receptor.
Clozapine did not effect [3H]raclopride binding except in negligible
amounts Oess than 7%) in the anterior amygdaloid, posterior hypothalamus,
and ventral medial portion of the CPu. Thus providing evidence that cloza
pine, at this predetermined concentration, does not have an effect on D2 re
ceptor binding and will have specific effects at the dopamine D,. receptor.
3

However, (+)apomorphine decreased [ H]raclopride in several brain areas.
Highest inhibitions of [3H]raclopride binding by (+)apomorphine (between
27% and 56%) were seen in the accumbens, both dorsal lateral and ventral
medial portions of the CPu, olfactory tubercle, SNc, and SNr.
[

3

Since

H]raclopride is specific for dopamine D2 and D3 receptors and (+)apomor

phine blocks a considerable portion of [3H]raclopride binding in areas
known to be rich in D2, it can be concluded that (+)apomorphine had signifi
cant binding at the dopamine D2 receptor. Therefore any inhibition of
3

[

H]YM-09151-2 by (+)apomorphine could be attributed to either D2 or D,.

receptor interactions.
A graphical representation of [3H]YM-09151-2 inhibition by raclopride
and clozapine in individual brain structures is shown in Figure 5. Data is
presented as the -log ratio of inhibiton of [3H]YM-09151-2 by clozapine di-
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Figure 5.

Dopamine D4 and D2 Receptor Locations In Rat Brain Deter
mined by [3H]YM-09151-2 Binding Inhibition by Clozapine and
Raclopride. Inhibition of binding values were obtained from
Tables 2-5 and ratios are plotted as -log of clozapine inhibition
of [3H]YM-09151-2 (fmol/mg tissue)/raclopride inhibition of
[3H]YM-09151-2 (fmol/mg tissue). Solid bars represent D4 dense
brain regions and hatched bars are D2 dense regions. Abbrevia
tions: A. = anterior, AI= agranular insular cortex, AMF = an
teromedial frontal cortex, BLA = basolateral amygdala, CAl-3
= fields of Amman's horn, D. = dorsal, L. = lateral, M.= medial,
P. = posterior, RSA and RSG = retrosplenial agranular and
granular cortex, Sag. = sagittals, SNc and SNr= substantia ni
gra pars compacta and reticulata, V. = ventral, VTA = ventral
tegmental area, (3.2), (1.2), and (-2.8) = mm bregma coronal sec
tions.
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vided by inhibition by raclopride, which is comparable to D4 receptor distri
bution divided by D2 receptor distribution. The brain region which had the
most D 4 versus D2 was the dentate gyrus (-3.48) followed by the CA3 of the
hippocampus (-3.27) and the anterior cingulate cortex (-3.01). The next
densest D, areas were the CAI (-1.69) and CA2 (-1.38) of the hippocampus,
frontal cortex area 1 of sagittal sections (-0.85), frontal cortex of 1.2 mm
bregma coronals (-0.79), hindlimb cortex (-0.63), frontal cortex area 2 ofsag
ittal sections (-0.61), occipital cortex (-0.60), entorhinal cortex (-0.48), tem
poral cortex (-.40), and septum (-0.32). A slightly higher density of D, re
ceptors than D 2 receptors was seen in the parietal cortex (-0.27), piriform
cortex (-0.24), RSG cortex (-0.21), frontal cortex of-2.8 mm bregma coronals
(-0.18), perirhinal cortex (-0.16), basolateral amygdaloid (-0.15), frontal cor
tex area 3 of 3.2 mm bregma coronals (-0.15), agranular insular cortex (0.13), cingulate cortex ofthe anteromedial frontal cortex (-0.11), frontal cor
tex area 2 of 3.2 mm bregma coronals (-0.05), and the RSA cortex (-.05).
Frontal cortex area 1 of 3.2 mm bregma sections represented the midpoint
where the amount of D4 was similar to D2 receptor density (0.01). Struc
tures identified thereafter characterize dopamine D2 receptor dense regions
starting lowest to highest with the dorsal hypothalamus (0.22) and follow
ing was the posterior hypothalamus (0.25), ventral hypothalamus (0.27), an
terior hypothalamus (0.49), SNr (0.61), olfactory tubercle (0.66), accumbens
(0.67), SNc (0.82), and the VTA (0.91). Both the ventral medial and dorsal

42
lateral portions of the CPu had the lowest dopamine D4 receptor density,
and was a region showing highest amount of dopamine D2 receptor (1.04
and 1.08, respectively).
Autoradiographic ImagesAutoradiographs are shown in Figures 7, 9, 11, and 13 and their re
spective brain structures are identified in Figures 6, 8, 10, and 12. Total
binding of [3H]YM-09151-2 compared to [3H]raclopride is demonstrated in
all figures (A and B), showing a high amount of [3H]YM-09151-2 binding to
the cortex, hippocampus, and septum, yet [3H]raclopride binding in these
areas was barely detectable. Binding of[3H]raclopride was high in the CPu,
accumbens, olfactory tubercle, SNc, SNr, and VTA, areas which also demon
strated high [3H]YM-09151-2 binding.
The autoradiographs from inhibition studies demonstrated that raclo
pride inhibition of[3H]YM-09151-2 was opposite to that of clozapine. In all
figures (A and C), raclopride inhibited radioligand binding in the CPu,
accumbens, olfactory tubercle, SNc, SNr, and VTA, and had little effect in
the septum and little or no effect in the cortex. In contrast, clozapine (all
figures; A and D) lacked inhibition of binding in the CPu, SNc, SNr, and
VTA, but reduced binding in the cortex and septum. Clozapine did inhibit
binding in the accumbens and olfactory tubercle, but had less of an effect
in these brain regions in comparison to raclopride. Another contrast was
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seen in the hippocampus where [3H]YM-09151-2 binding was reduced by
clozapine and raclopride had no effect.
The autoradiographs illustrate that raclopride specific effects were in
D 2 brain areas which included the CPu, accumbens, olfactory tubercle, SNc,
SNr, and vrA, while [3H]YM-09151-2 binding sites not labelled by [3H]rac
lopride and clozapine inhibitory effects were apparent in the cerebral cortex
and hippocampus, areas that have D4 receptor mRNA.
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Figure 6.

Rat Brain Coronal Section at Bregina Level 1.20 mm as Depict
ed in the Rat Brain Atlas (Paxinos & Watson, 1986). Abbrevia
tions: AI= aganular insular cortex, CPu = caudate putamen.
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[3H]YM-09I51-2

C

[3H]YM-09151-2 + Raclopride

[3H]Raclopride

D [3H]YM-09151-2 + Clozapine

••
Figure 7.

Autoradiographic Images of[3 H]YM-09151-2 and [3 H]Raclopride
Total Binding in Rat Brain 1.2 mm Bregma Coronal Sections.
Structures identified in Figure 6. Optical density scale: white
represents high radioligand binding. [3 HJYM-09151-2 binding
(A) was greater than [3H]raclopride (B) in the cerebral cortex
and septum, and was slightly more than [3H]raclopride in the
accumbens and olfactory tubercle. [3H]Raclopride binding was
greater than [3H]YM-09151-2 in the CPu. Raclopride (C) inhib
ited binding in the CPu, accumbens, and olfactory tubercle, and
had little effect on binding in the cortex and septum. Clozapine
(D) reduced binding in the cortex and septum, had a slight re
duction on binding in the accumbens and olfactory tubercle, and
had little if any effect on binding in the CPu.
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Figure 8.

Rat Brain Coronal Section at Bregrna Level -4.8 mm as Depict
ed in the Rat Brain Atlas (Paxinos & Watson, 1986). Abbrevia
tions: CAl-3 = fields of Amman's horn, DG = dentate gyrus,
Ent= entorhinal cortex, PRh= perirhinal cortex, RSA= retro
splenial agranular cortex, RSG= retrosplenial granular cortex.
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[3H]YM-09151-2

C [3H]YM-09151-2 + Raclopride

Figure 9.

[3H]Raclopride

[3H]YM-09151-2 + Clozapine

Autoradiographic Images of[3H]YM-09151-2 and [3H]Raclopride
Total Binding in Rat Brain -4.8 mm Bregma Coronal Sections.
Structures identified in Figure 8. Optical density scale: white
represents high radioligand binding. A high density of[3HJYM09151-2 binding (A) was detected in the cerebral cortex and
hippocampus where [ 3H]raclopride binding (B) was virtually
absent. Both radioligands bound equally to the SNc, SNr, and
VTA. Raclopride (C) inhibited binding in the SNc, SNr, VTA,
had little effect in the cortex, and no effect in the hippocampus.
Clozapine (D) reduced binding in the hippocampus, had a slight
effect in the cortex, and no effect on binding in the SNc, SNr,
and VTA.

•

Tubercle

Figure 10. Rat Brain Sagittal Section at Lateral Level 1.9 mm as Depicted
in the Rat Brain Atlas (Paxinos & Watson, 1986). Abbrevia
tions: CAl-3 = fields of Ammon's horn, CPu = caudate puta
men, DG = dentate gyrus, LH = lateral hypothalamus, RSA =
retrosplenial agranular cortex, RSG = retrosplenial granular
cortex, SNc = substantia nigra pars compacta, SNr = substantia
nigra pars reticulata.
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[3H]Raclopride

[3H]YM-09151-2

C

[3H]YM-09151-2 + Raclnpride

D

[JH]YM-09151-2 + Clozapine

Figure 11. Autoradiographic Images of[3 H]YM-09151-2 and [3H]Raclopride
Total Binding in Rat Brain 1.9 mm Lateral Sagittal Sections.
Structures identified in Figure 10. Optical density scale: white
represents high radioligand binding. A high density of[3H]YM09151-2 binding (A) was detected in the cerebral cortex and
hippocampus where [3H]raclopride binding (B) was barely de
tectable. [3H]YM-09151-2 had a slightly higher amount ofbind
ing than [3H]raclopride in the accumbens and olfactory tubercle,
and [3H]raclopride binding was higher in the CPu. Both radio
ligands bound equally to the SNc and SNr. Raclopride (C)
inhibited binding in the CPu, SNc, SNr, accumbens, olfactory
tubercle, had slight inhibition in the cortex, and no reduction
of binding in the hippocampus. Clozapine (D) reduced binding
in the cortex and hippocampus, had a slight reduction of
binding in the accumbens and olfactory tubercle, had little if
any effect in the CPu, and no effect in the SNc and SNr.
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Figure 12. Rat Brain Horizontal Section at Interaural Level 5.40 mm as
Depicted in the Rat Brain Atlas (Paxinos & Watson, 1986).
Abbreviations: AI= agranular insular cortex, AM= anterome
dial, CAl-3= fields of Amman's horn, Cing.= cingulate, Ent=
entorhinal cortex,• PRh = perirhinal cortex.
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[3H]Raclopride

[3H]YM-09151-2

C

[3H]YM-09151-2 + Raclopride

D

[3H]YM-09151-2 + Clozapine

Figure 13. Autoradiographic Images of[3 H]YM-09151-2 and [3 H]Raclopride
Total Binding in Rat Brain 5.4 mm Interaural Horizontal Sec
tions. Structures identified in Figure 12. Optical density scale:
white represents high radioligand binding. A high density of
3
[ H]YM-09151-2 binding (A) was detected in the cerebral cortex
and hippocampus where [ 3H]raclopride binding (B) was barely
detectable. [3H]YM-09151-2 binding was greater than than
3
[ H]raclopride in the septum, and [ H]raclopride binding was
greater in the CPu. Raclopride (C) inhibited binding in the
CPu, had little effect in the septum and little if any effect in
the cortex, and no reduction of binding in the hippocampus.
Clozapine (D) reduced binding in the cortex, hippocampus,
septum, and had little if any affect in the CPu.
3

DISCUSSION
Dopamine D4 Receptor Distribution Determined From
Radioligand Binding Differences
Radioligand concentrations used in the study were twice the concen
tration of their �'s obtained from whole rat brain studies. This allows for
equivalent receptor occupancy of the D2-type receptors D2 , D3 , D4 with
3

[

H]YM-09151-2 and D2 and D3 using [3H]raclopride and radioligand binding

differences can be compared. The amount of receptors labelled by [3H]YM09151-2 and [3H]raclopride were similar in the SNc, SNr, and VTA, sugges
ting equivalent receptor occupancy had been reached at the radioligand con
centrations used. Since these brain areas are D2 and D3 regions, dopamine
D2 or D3 receptors will be labelled equivalently with the radioligands and
a difference in radioligand binding densities where [3H]YM-09151-2 binding
is greater than [3H]raclopride would represent D4 receptor distribution. The
dopamine D4 receptors were localized in the cerebral cortex, basolateral
amygdala, hippocampus, septum, nucleus accumbens, and olfactory tubercle
as [3H]YM-09151-2 bound to more receptors than [3H]raclopride in these re
gions.
The binding density of[3H]YM-09151-2 and [3 H]raclopride was expec
ted to be equivalent in the CPu as demonstrated in the SNc and SNr since
52
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these structures contain D2 andD receptor mRNA and a lack ofD,. How
3

ever,[3H]raclopride binding was slightly higher than[3H]YM-09151-2 in the
CPu. The discrepancy may be due to comparing radioligand concentrations
presumed to be at receptor saturation levels and not Bmu: values from
Scatchard plots. Yet it appears that the reduction of[3H]YM-09151-2 bind
ing may be inherent to the CPu as the binding was not reduced in other
structures quantified. Serotonin 5-HT2 receptors blocked by ketanserin in
H]YM-09151-2 incubations may be involved in the reduction of binding in

3

[

the CPu. Investigations have demonstrated that dopamine and 5-HT2 re
ceptors may be located on the same neuron in the CPu (Descarries, Audet,
Doucet, Garcia, Oleskevich, Seguela, Soghomonian, & Watkins, 1990;
Schmidt, Black, Taylor, Fadayel, Humphreys, Nieduzak, & Sorensen, 1992),
which indicates that binding of ketanserin to 5-HT2 receptors may induce
a conformational change in dopamineD2 receptors and could explain the re
duction of [3H]YM-09151-2 binding in this structure.
It can not be ascertained from this study why binding is reduced in
the CPu, yet the observations that[3H]raclopride will bind to dopamineD2
and D3 receptors either equivalently or higher than [3H]YM-09151-2 sug
gests that a difference in radioligand binding where [3H]YM-09151-2 bind
ing is higher would still represent brain regions that have D, receptors.
The blocking studies performed with raclopride and clozapine using
H]YM-09151-2 will further confirm the distribution of the dopamine D2 -

3

[
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type receptors.
Dopamine D2 and D4 Receptor Locations Determined From
Radioligand Blocking Studies
The density of receptors labelled by [3H]ra.clopride was found to be
highest in the CPu> accumbens> olfactory tubercle> SNc> SNr> VTA
> hypothalamus and sparse binding in cortical regions. This binding distri
bution is consistent with previous investigations of [3H]raclopride binding
localization (Mansour, Meador-Woodruff, Bunzow, Civelli, Akil, & Watson,
1990), and the distribution of [3HJraclopride has been shown to correlate
with dopamine D2 receptor mRNA distribution (Mansour, Meador-Woodruff,
Bunzow, Civelli, Akil, & Watson, 1990). Thus, brain regions labelled by
3

[

H]raclopride represented D2 locations. Since the [3H]YM-09151-2 binding

sites inhibited by raclopride correlated well with the binding distribution
of [3H]raclopride in the same brain regions, it is apparent that raclopride
inhibition of [3H]YM-09151-2 was at the dopamine D2 receptor.
At the concentration used, clozapine had no inhibitory effect on
[3H]raclopride binding except in the anterior amygdaloid, posterior hypo
thalamus, and ventral medial portion of the CPu where only a maximal in
hibition of 7% was seen. It can be concluded that clozapine, at this prede
termined concentration, does not significantly interfere with dopamine D2
3
receptor binding
• and its inhibitory effect on [ H]YM-09151-2 binding is at

the dopamine D4 receptor.
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Binding inhibition of[3H]YM-09151-2 by clozapine was demonstrated
in the cerebral cortex, hippocampus, basolateral amygdala, septum,
accumbens, and olfactory tubercle, and had low inhibition in the CPu and
no effect in the SNc, SNr, or VTA. These findings are consistent with hu
man dopamine D4 mRNA distribution in rat or monkey (Mansour, Meador
Woodruff, Burke, Bunzow, Akil, Van Toi, Civelli, & Watson, 1991; Van Toi,
Bunzow, Guan, Sunahara, Seeman, Niznik, & Civelli, 1991; O'Malley, Har
mon, Tang, & Todd, 1992). Clozapine blockade of [3H]YM-09151-2 was
higher than raclopride inhibition in the cerebral cortex, hippocampus, baso
lateral amygdala, and septum revealing that the D, receptor is more dense
than D2 in these brain regions.
(+ )Apomorphine was able to inhibit [3H]raclopride binding and de
monstrated inhibition of [3H]YM-09151-2 similar to raclopride and cloza
pine. Thus, (+)apomorphine was determined to have substantial binding
affinity for both D2 and D4 receptors and was not used to discern D2 from
D4 regions.
Dopamine D4 Receptor Distribution
Clozapine inhibition of[3H]YM-09151-2 binding was demonstrated in
the same structures that had a higher density of [3H]YM-09151-2 binding
sites in comparison to [3H]raclopride. These observations allow high confi
dence in the determination of the D4 receptor distribution since both studies
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identified D, receptors in the same structures. The dopamine D 4 receptor
was found in the cerebral cortex, hippocampus, basolateral amygdala, sep
tum, nucleus accumbens, and olfactory tubercle, with low or undetectable
levels found in the CPu and an absence of receptors in the SNc, SNr, and
VTA. Comparatively, a differential distribution exists between D, and D 2
receptors, as D2 receptors were undetectable in the hippocampus, basolater
al amygdala, and high amounts were found in the CPu, SNc, SNr, and
VTA. In addition, dopamine D4 receptors were located in higher amounts
than dopamine D 2 receptors in the cerebral cortex and septum. More im
portantly is the observations that the hippocampus, frontal cortex, and an
terior cingulate cortex have a higher density of D4 than D 2 receptors. All
three structures have been implicated in the pathology of schizophrenia
where dopamine appears to have a role in the disease process.
Role of Hippocampus in the Pathology of Schizophrenia
Several structural abnormalities of the hippocampus are detected in
postmortem schizophrenic brain, and correlation evidence has indicated
that the abnormalities of the hippocampus are associated with the positive
symptoms of paranoid schizophrenia which are that of excitement, agita
tion, euphoria, and delusions (Bischoff, 1986; Brown, Colter, & Corsellis,
Crow, Frith, Jagoe, Johnstone, & Marsh, 1986; Roberts, 1990).
Several investigations have demonstrated a role of dopamine in the
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hippocampus in relation to schizophrenic symptoms. Krieckhaus, Donahoe,
& Morgan (1992) have proposed that delusions of paranoid schizophrenia
are caused by hyperactivity of DA sensitive neurons in the hippocampus.
The hypothesis is based on evidence of Stein and Belluzzi (1989) which
showed that DA prolongs and potentiates cell activity when applied to the
hippocampus, and this effect was reduced by anti.psychotic drugs.
Other data demonstrated a correlation between the potency of anti.
psychotics as inhibitors of [3H]spiperone, a D2-type radioligand, in hippo
campus with their ability to antagonize amphetamine stereotypies - a condi
tion produced by DA agonism which elicits schizophrenia symptoms (Bisch
off, Vassout, & Waldmeier, 1986).
The evidence suggests that D2-type receptor antagonism in the hippo
campus may restore abnormal limbic system functioning in schizophrenia.
Role of Frontal and Anterior Cingulate Cortex
in Schizophrenia
The frontal and anterior cingulate cortex show a different pathological
behavioral function in the etiology of schizophrenia. The frontal cortex may
be involved with negative symptoms of schizophrenia such as social with
drawal, depressed affect, and poverty of thought and speech (Mesulam
1990; Goldberg, Berman, & Weinberger, 1989), and the anterior cingulate
cortex contributes to disorders in the form of thought and inappropriate af
fect (Liddle, Friston, Frith, & Frackowiak, 1992) and has a role in produc-
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ing auditory hallucinations (Cleghorn, Garnett, Nahmias, Brown, Kaplan,
Szechtman, Szechtman, Franco, Dermer, & Cook, 1990; Cleghorn, Franco,
Szechtman, Kaplan, Szechtman, Brown, Nahmias, & Garnett, 1992).
A general trend of reduced neuronal numbers and neuronal density
is found between schizophrenic brain and normal controls in frontal and an
terior cingulate cortex (Benes, Davidson, & Bird, 1986). Of most impor
tance is the loss of interneurons in both systems, since the specific inter
neurons lost have an inhibitory effect on a specific type ofactivated neuron
(AN) (Benes, 1993). A dopaminergic role is thought to be prevalent in this
system in healthy individuals where its function would be to inhibit the in
terneuron from causing an inhibition ofthe AN, allowing the AN to contin
ue to be active (Onteniente, Simon, Taghzouti, Geffard, Moal, & Calas,
1987; Goldman-Rakic, Leranth, William, Mons, & Geffard, 1989; Benes,
1993). It is suggested that in a situation where there is a loss ofinterneu
rons, DA neurons will form redundant connections on remaining interneu
rons, and as a result, there is an excess ofneuronal firing ofthe AN (Benes,
1993). Antipsychotic drugs appear to antagonize these effects ofDA activi
ty and alleviate excess neuronal firing of the AN (Marco, Mao, Revuelta,
Peralta, & Costa, 1978; Benes, 1993).
Several other pieces of evidence demonstrate a role of dopamine in
the two brain regions. The dopamine agonist apomorphine induced an in
crease in regional cerebral blood flow in the anterior cingulate cortex in

59
healthy individuals (Grasby, Friston, Bench, Cowen, Frith, Liddle, Frack
owiak, & Dolan, 1993), and haloperidol, a D:i-type antipsychotic agent, de
creased glucose metabolism in both the anterior cingulate and frontal cor
tex in healthy subjects (Bartlett, Brodie, Simkowitz, Dewey, Rusinek, Wolf,
Fowler, Volkow, Smith, Wolkin, et al., 1994).
Therefore, antipsychotics decrease DA neuronal activity in the frontal
cortex and anterior cingulate cortex and may alleviate schizophrenic symp
toms.
· Since there is a higher density of dopamine D4 receptors in compari
son to D2 in the hippocampus, frontal cortex, and anterior cingulate cortex,
and antipsychotic agents reduce DA activity in these regions, it is suggested
that DA antagonistic activity of antipsychotics may be modulated by D4 re
ceptors in these regions.

CONCLUSIONS
The atypical antipsychotic clozapine in comparison to typical antipsy
chotics had been shown previously to be more effective in decreasing posi
tive and negative symptoms in patients that have schizophrenia (Claghorn,
Honigfeld, Abuzzahab, Wang, Steinbook, Tuason, & Klerman, 1987; Kane,
Honigfeld, Singer, and Meltzer; 1988; Metzler, 1989; Metzler, 1990). Cloza
pine's selectivity for the D4 and the present findings ofD 4 receptor densities
being higher than D2 in the hippocampus, anterior cingulate cortex, and
frontal cortex, structures known to be involved in producing positive and
negative symptoms of schizophrenia, suggest that clozapine's mechanism
of action in producing antipsychotic efficacy may be at the D4 receptor. The
lack of clozapine blockade in the nigrostriatal system correlates with the ob
servation that there is little or undetectable extrapyramidal side effects as
sociated with clozapine treatment of schizophrenia. These findings are con
sistent with the working hypothesis that blockade of the dopamine D4 re
ceptor may reduce schizophrenic symptoms while avoiding extrapyramidal
side effects.
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Appendix A
Protocol Clearance From the Corporate
Animal Welfare Committee
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CNS Diseases Research
The Upjohn Company
JO! Henrietta Street
Kalamazoo, MI 49001
F�bruary 23,

1993

Nancy C. Stratman
Western Michigan University
CNS Diseases Research
The Upjohn Company
JO! Henrietta Street
Kalamazoo, Ml 49001
Dear Ms. Stratman,
This letter is to inform you that :1ou have approval from the
Corpprate Animal Welfare Committee to use Sprague-Dawley rats
for your Master Thesis research at Western Michigan
University.
Approved animal work, which is done at The Upjohn Company,
involves sacrificing rats, brain dissection, and brain
slicing in which brain tissue is used for autoradiographic
and receptor binding analysis.
Animal usage protocols are effective from January 1992 to
January 1993 (AUPU 128-2-8210-4), and from January 1993 to
January 1994 (AUPII 132-2-8210-2).
lf you have any further questions please contact me at the
above address.

Philip F. 1/onVoightlander,,Ph.D., D.V . .\\.
Director:CNS Diseases Research,
The Upjohn Company
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c�s Diseases Research
The Upjohn Company
301 Henrietta Street
Kalamazoo, MI 49001
May 17, 1995
�ancy C. Stratman
Western Michigan University
_C�S Diseases Research
The Upjohn Company
301 Henrietta St=eet
�alamazoo, MI 49001
Dear Ms. Stratman,
:his letter is to inform you that you have approval f=om the Corporate .\nimal
Welfare Committee to use S9rague-Da-..,ley =ats for you= �aster Thesis research at
Western Michigan University.
Ap9roved animal -..,erk, -..,hich is done at The Upjohn Company, involves sacrificing
=ats, brain dissection, and brain 3licing in -..,hich :i=ain tissue is t.:sed i:or
autoradiographic receptor binding analysis.
':'!":e animal usage ;:,rotocol is effec::.·,e f=om January :i.994 :o Janua=y 1995 (AUP!t
:32-01-3-8210)
you have any further questions ?lease contact me at :he above address.

?hilip c. VonVoightlander, ?h.D., J.V.�.
Di=ector
CIS Diseases Research
':'te Upjohn Company
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